Dumont & Blake Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.05M Sell
12,139
-994
-8% -$214K 0.69% 36
2026
Q1
$2.86M Sell
13,133
-210
-2% -$46.6K 0.71% 35
2025
Q4
$3.05M Sell
13,343
-202
-1% -$46K 0.73% 28
2025
Q3
$3.14M Sell
13,545
-304
-2% -$61.9K 0.76% 26
2025
Q2
$2.57M Sell
13,849
-40
-0.3% -$7.43K 0.67% 35
2025
Q1
$2.91M Sell
13,889
-99
-0.7% -$19.2K 0.82% 25
2024
Q4
$2.49M Sell
13,988
-115
-0.8% -$21.1K 0.67% 34
2024
Q3
$2.79M Sell
14,103
-14,309
-50% -$2.67M 0.74% 32
2024
Q2
$4.87M Buy
28,412
+12,786
+82% +$2.12M 0.69% 34
2024
Q1
$2.85M Sell
15,626
-466
-3% -$80.3K 0.82% 26
2023
Q4
$2.49M Sell
16,092
-1,347
-8% -$196K 0.77% 29
2023
Q3
$2.6M Sell
17,439
-47
-0.3% -$6.9K 0.88% 23
2023
Q2
$2.36M Sell
17,486
-1,115
-6% -$164K 0.77% 31
2023
Q1
$2.96M Sell
18,601
-75
-0.4% -$11.5K 1% 16
2022
Q4
$3.02M Sell
18,676
-237
-1% -$36.3K 1.07% 16
2022
Q3
$2.54M Sell
18,913
-1,060
-5% -$152K 0.95% 20
2022
Q2
$3.06M Sell
19,973
-138
-0.7% -$21.1K 1% 20
2022
Q1
$3.26M Sell
20,111
-477
-2% -$69.3K 0.89% 23
2021
Q4
$2.79M Buy
20,588
+373
+2% +$44.1K 0.73% 33
2021
Q3
$2.18M Buy
20,215
+21
+0.1% +$2.4K 0.62% 42
2021
Q2
$2.27M Buy
20,194
+114
+0.6% +$12.8K 0.65% 40
2021
Q1
$2.17M Buy
20,080
+14
+0.1% +$1.5K 0.67% 39
2020
Q4
$2.15M Sell
20,066
-924
-4% -$88.8K 0.73% 34
2020
Q3
$1.84M Buy
20,990
+452
+2% +$42.6K 0.7% 38
2020
Q2
$2.02M Buy
20,538
+91
+0.4% +$8.01K 0.84% 31
2020
Q1
$1.56M Sell
20,447
-195
-0.9% -$16.6K 0.8% 36
2019
Q4
$1.83M Buy
20,642
+150
+0.7% +$12.5K 0.72% 41
2019
Q3
$1.55M Sell
20,492
-665
-3% -$45.6K 0.65% 42
2019
Q2
$1.54M Buy
21,157
+90
+0.4% +$7.07K 0.64% 41
2019
Q1
$1.7M Sell
21,067
-55
-0.3% -$4.5K 0.72% 37
2018
Q4
$1.95M Sell
21,122
-1,245
-6% -$109K 0.91% 27
2018
Q3
$2.12M Buy
22,367
+822
+4% +$78K 0.82% 31
2018
Q2
$2M Sell
21,545
-1,750
-8% -$171K 0.84% 33
2018
Q1
$2.21M Buy
23,295
+25
+0.1% +$2.75K 0.94% 25
2017
Q4
$2.25M Hold
23,270
0.91% 25
2017
Q3
$2.07M Sell
23,270
-300
-1% -$22.8K 0.89% 29
2017
Q2
$1.71M Buy
23,570
+1,875
+9% +$126K 0.76% 38
2017
Q1
$1.41M Buy
21,695
+120
+0.6% +$7.54K 0.64% 44
2016
Q4
$1.35M Buy
21,575
+20
+0.1% +$1.22K 0.63% 47
2016
Q3
$1.36M Sell
21,555
-200
-0.9% -$12.9K 0.67% 44
2016
Q2
$1.35M Sell
21,755
-600
-3% -$36.6K 0.68% 44
2016
Q1
$1.28M Sell
22,355
-175
-0.8% -$9.75K 0.66% 46
2015
Q4
$1.33M Buy
22,530
+850
+4% +$49K 0.68% 45
2015
Q3
$1.18M Hold
21,680
0.64% 54
2015
Q2
$1.46M Buy
21,680
+1,375
+7% +$89.8K 0.71% 48
2015
Q1
$1.19M Buy
20,305
+100
+0.5% +$6.04K 0.58% 66
2014
Q4
$1.32M Sell
20,205
-200
-1% -$12.6K 0.65% 57
2014
Q3
$1.18M Sell
20,405
-150
-0.7% -$8.33K 0.61% 62
2014
Q2
$1.16M Sell
20,555
-675
-3% -$35.4K 0.58% 67
2014
Q1
$1.09M Sell
21,230
-390
-2% -$19.7K 0.57% 69
2013
Q4
$1.14M Sell
21,620
-1,315
-6% -$64.6K 0.59% 67
2013
Q3
$1.03M Sell
22,935
-65
-0.3% -$2.88K 0.49% 85
2013
Q2
$951K Buy
+23,000
New +$1.01M 0.57% 74

Other funds holding ABBV

Dumont & Blake Investment Advisors's ABBV Position: Q2 2026 in Review

Dumont & Blake Investment Advisors reduced its AbbVie (ABBV) stake by 7.6% in Q2 2026, selling an estimated $214K and leaving 12,139 shares worth $3.05M. The position accounts for 0.69% of the portfolio, ranked #36.

Dumont & Blake Investment Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.87M in Q2 2024. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Dumont & Blake Investment Advisors held 12,139 shares of AbbVie worth $3.05M as of Q2 2026.
  • Dumont & Blake Investment Advisors sold 994 AbbVie shares in Q2 2026, an estimated $214K.
  • AbbVie made up 0.69% of Dumont & Blake Investment Advisors's portfolio in Q2 2026, its #36 holding.
  • Dumont & Blake Investment Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Dumont & Blake Investment Advisors's AbbVie position peaked at $4.87M in Q2 2024.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Dumont & Blake Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.